Appili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025
Rhea-AI Summary
Appili Therapeutics (TSX: APLI; OTCPink: APLIF) announced that President and CEO Don Cilla will participate in Aditxt Weekly Update on April 4, 2025, alongside Aditxt CEO Amro Albanna. The discussion will focus on:
- The company's ongoing going-private transaction with Aditxt
- $117 million in new federal funding applications
- The growing threat of emerging infectious diseases
- Appili's near-to-market portfolio addressing unmet patient needs
The company highlighted its success in securing non-dilutive funding, including $33.2 million in prior government awards. The event will include a Q&A session, with Appili planning to participate in additional Aditxt Weekly Updates throughout the year.
Positive
- Substantial potential funding with $117 million in new federal applications submitted
- Strong track record of securing non-dilutive funding with $33.2 million in prior government awards
Negative
- Going-private transaction may impact current shareholders' ownership structure
News Market Reaction
On the day this news was published, APLIF declined 2.39%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Event exploring the escalating threat of emerging infectious diseases
Discussion covering going-private transaction with Aditxt, strategic growth partner
HALIFAX, Nova Scotia, April 02, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that its President and CEO, Don Cilla, Pharm.D., M.B.A., will join Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt") Co-founder and CEO, Amro Albanna, for the Aditxt Weekly Update on April 4, 2025. The discussion will cover the Company’s recent operational highlights, including
Dr. Cilla will join Aditxt to explore the escalating threat of emerging infectious diseases and highlight the vital role of strategic partnerships in developing innovative treatments and improving global public health. The Aditxt Weekly Update will also provide insights into Appili’s diverse near-to-market portfolio, designed to address critical unmet patient needs.
Additionally, the discussion will highlight Appili’s proven track record in securing non-dilutive funding, showcasing
Participants are encouraged to register in advance by clicking here. The event will also include a Q&A session, with questions welcomed at info@appilitherapeutics.com.
Appili will join additional Aditxt Weekly Updates throughout the year.
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com.
Forward Looking Statements
This news release contains “forward-looking statements”, including with respect to the potential for partnered projects to be developed, the potential that Appili will receive government awards and / or contracts related to its proposal submissions, the availability of future funding under the USAFA cooperative agreement, the Company’s development plan with respect to ATI-1701 and the expected timing and process to complete the Transaction. Wherever possible, words such as “may,” “would,” “could,” “should,” “will,” “anticipate,” “believe,” “plan,” “expect,” “intend,” “estimate,” “potential for” and similar expressions have been used to identify these forward-looking statements. These forward-looking statements reflect the current expectations of the Company’s management for future growth, results of operations, performance and business prospects and opportunities and involve significant known and unknown risks, uncertainties and assumptions, including, without limitation, those listed in (i) the annual information form of the Company dated June 25, 2024, (ii) the Circular, and (iii) and the other filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedarplus.ca). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise, except as required by law.
Media Contact:
Jenna McNeil, Corporate Affairs and Communications Manager
Appili Therapeutics
E: JMcNeil@AppiliTherapeutics.com
Investor Relations Contact:
Don Cilla, Pharm.D. M.B.A.
Appili Therapeutics
E: Info@AppiliTherapeutics.com
FAQ
What is the total value of Appili Therapeutics' (APLIF) new federal funding applications?
How much government funding has APLIF previously secured?
When is Appili Therapeutics (APLIF) CEO participating in the Aditxt Weekly Update?
What is the status of APLIF's going-private transaction with Aditxt?
